Abstracts tagged "prognostic factors"

Abstract Number: 2289 • 2017 ACR/ARHP Annual Meeting
Individualized Prediction of Early Remission on Medication in Juvenile Idiopathic Arthritis
Jaime Guzman¹, Andrew Henrey², Thomas Loughin², Kiem Oen³, Natalie J. Shiff⁴, Roberta Berard⁵, Roman Jurencak⁶, Adam Huber⁷, Kerstin Gerhold⁸, Susanne Benseler⁹, Ciarán M. Duffy¹⁰ and Lori Tucker¹, ¹BC Children's Hospital, Vancouver, BC, Canada, ²Statistics and Actuarial Science, Simon Fraser University, Burnaby, BC, Canada, ³Department of Pediatrics and Child Health University of Manitoba, Winnipeg, MB, Canada, ⁴University of Florida, Gainesville, FL, ⁵Pediatrics, Children's Hospital, London Health Sciences Centre, London, ON, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷IWK Health Centre, Halifax, NS, Canada, ⁸Pediatrics, University of Manitoba, Winnipeg, MB, Canada, ⁹Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ¹⁰Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada
Background/Purpose: The Research in Arthritis in Canadian Children emphasizing Outcomes cohort (ReACCh-Out) showed a 45% chance of attaining inactive disease within a year of…
Abstract Number: 2909 • 2017 ACR/ARHP Annual Meeting
Only Very High Radiographic Progression Affects HAQ-DI, Results from the Swiss Scqm Cohort
Ruediger Mueller¹, Reto Thalmann², Hendrik Schulze-Koops³, Nicole Graf⁴ and Johannes von Kempis², ¹Rheumatology, MD, St. Gallen, Switzerland, ²Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ⁴Graf Biostatistics, Winterthur, Switzerland
Background/Purpose: The aim of treatment of rheumatoid arthritis is to control disease activity and to inhibit joint damage. Progression of damage is analysed by conventional…
Abstract Number: 583 • 2017 ACR/ARHP Annual Meeting
Associations of Changes of Radiographic Disease and Spinal Mobility Measures in Ankylosing Spondylitis
Mark Hwang^1,2,3, Michael Weisman⁴, MinJae Lee⁵, Lianne S. Gensler⁶, Matt Brown⁷, Amirali Tahanan⁵, Laura A. Diekman⁸, Thomas Learch⁹, Seth Eisen¹⁰, Mohammad H. Rahbar⁵, Michael Ward¹¹ and John D. Reveille¹², ¹Medicine, University of Texas-McGovern Medical School, Houston, TX, ²Internal Medicine-Rheumatology, University of Texas-McGovern Medical School, Saint Louis, MO, ³Washington University at Saint Louis School of Medicine, Saint Louis, MO, ⁴Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ⁵Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁶Medicine/Rheumatology, UCSF, San Francisco, CA, ⁷Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Brisbane, Australia, Brisbane, Australia, ⁸Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ⁹Radiology, Cedars Sinai Medical Center, Los Angeles, CA, ¹⁰Division of Rheumatology, Washington University at Saint Louis School of Medicine, St Louis, MO, ¹¹NIH/NIAMS, Bethesda, MD, ¹²University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Metrology indices aimed as assessing spinal mobility in ankylosing spondylitis (AS) patients are used in clinical trials and clinical practice to assess disease severity…
Abstract Number: 727 • 2017 ACR/ARHP Annual Meeting
Survival and Clinical-Capillaroscopic Characteristics of French Canadian Systemic Sclerosis Patients: Analysis Based on Systemic Sclerosis Autoantibodies and the Novel Anti-BICD2 Autoantibody
Boyang Zheng¹, Michael Mahler², Jean-Luc Senécal³, France Joyal⁴ and Martial Koenig⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada, ²Research and Development, Inova Diagnostics, San Diego, CA, ³Rheumatology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada, ⁴Internal Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada, ⁵Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) autoantibodies (aAbs) are invaluable for SSc diagnosis and prognosis. Anti-centromere (ACA), anti-topoisomerase I (ATA) and anti-RNA polymerase III (RNAP) have been…
Abstract Number: 1884 • 2016 ACR/ARHP Annual Meeting
Esophageal Dilation and Interstitial Lung Disease Incidence and Progression in Systemic Sclerosis
Kimberly Showalter¹, Aileen Hoffmann², Carrie Richardson^3,4, Julia (Jungwha) Lee⁵, David Aaby⁶, Rishi Agrawal⁷, Jane Dematte⁸, Rowland W. Chang⁹ and Monique Hinchcliff¹⁰, ¹Internal Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, ²Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Department of Medicine, McGaw Medical Center of Northwestern University, Chicago, IL, ⁴Department of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Preventive Medicine/Biostatistics, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Pulmonology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). Esophageal dysfunction and aspiration may play a role in SSc-ILD.…
Abstract Number: 1896 • 2016 ACR/ARHP Annual Meeting
Efficacy of Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Survival of Patients with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis and Other Connective Tissue Diseases
Sumiaki Tanaka¹, Yu Matsueda¹, Gakuro Abe², Jun Okada³ and Shunsei Hirohata¹, ¹Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ²Kitasato University School of Medicine, Sagamihara, Japan, ³Nutritional management, Kitasato Junior Collage of health and Hygienic Sciences, Minami-Uonuma, Japan
Background/Purpose: Survival of patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), especially systemic sclerosis (SSc), is poorer than that of patients…
Abstract Number: 2019 • 2016 ACR/ARHP Annual Meeting
Faces in Motion: Clinical Subtyping in Scleroderma Using Changes in Forced Vital Capacity
Colin Ligon¹, Peter Schulam², Suchi Saria³, Fredrick M. Wigley⁴, Robert Wise⁵ and Laura K. Hummers⁶, ¹Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, PA, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Pulmonology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Prognostication in scleroderma has historically depended on using static measures such as antibody status and extent of skin involvement to stratify risk of mortality…
Abstract Number: 2081 • 2016 ACR/ARHP Annual Meeting
Dermal Temperature Is an Excelent Prognostic Indicator to Guide RA Therapy
JoAnn Ball¹ and Maria Greenwald², ¹rheumatology, Desert Medical Advances, Palm Deseret, CA, ²Rheumatology, Desert Medical Advances, Palm Desert, CA
Background/Purpose: Nurses and rheumatology extenders can rapidly identify rheumatoid arthritis (RA) patients who flare, with high predictive value for which individual is at high risk…
Abstract Number: 2478 • 2016 ACR/ARHP Annual Meeting
Impact of Poor Prognostic Factors on Treatment Decisions in Clinical Practice in Patients with Rheumatoid Arthritis: Findings from a US Observational Cohort
LR Harrold¹, E Alemao², HJ Litman³, SE Connolly⁴, S Kelly², W Hua³, L Rosenblatt², S Rebello⁵ and JM Kremer⁶, ¹University of Massachusetts Medical School, Worcester, MA, ²Bristol-Myers Squibb, Princeton, NJ, ³Corrona, Southborough, MA, ⁴Department of Immunology and Inflammation, Bristol-Myers Squibb, Princeton, NJ, ⁵Epidemiology, Corrona, Southborough, MA, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Poor prognostic factors can determine the extent of disease progression, disability and treatment outcomes in patients (pts) with RA. It is currently unknown whether…
Abstract Number: 2487 • 2016 ACR/ARHP Annual Meeting
In Patients with Rheumatoid Arthritis in Clinical Remission Undergoing Treatment Tapering Tenosynovitis and Synovitis Detected By Ultrasonography Predict Disease Flare
Antonella Adinolfi¹, Giovanni Cagnotto², Filippo Luccioli³, Claudio Mastaglio⁴, Giulia Mirabelli³, Daniela Rossi⁵, Silvia Rossi², Emanuela Bellis⁶, Greta Carrara⁷, Carlo Alberto Scirè⁸, Annamaria Iagnocco⁹ and Garifallia Sakellariou², ¹Policlinico le Scotte, Siena, Italy, ²University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ³University of Perugia, Perugia, Italy, ⁴Moriggia-Pelascini, Gravedona, Italy, ⁵Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ⁶Rheumatology, Ospedale Mauriziano, Turin, Italy, ⁷Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ⁸Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, ⁹Sapienza University of Rome, Rome, Italy
Background/Purpose: Ultrasound (US) detected synovitis predicts flare in patients with rheumatoid arthritis (RA), while the role of tenosynovitis has yet to be established. The aim…
Abstract Number: 3218 • 2016 ACR/ARHP Annual Meeting
Synovial Mast Cells Associate with High Disease Activity and Predict Radiographic Progression at 12 Months in Patients with Early Rheumatoid Arthritis
Felice Rivellese¹, Frances Humby¹, Stephen Kelly¹, Amato de Paulis², Gianni Marone² and Costantino Pitzalis¹, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ²Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy
Background/Purpose: Mast cells (MCs) are immune cells present in the synovial membrane and implicated in the pathogenesis of Rheumatoid Arthritis, although their exact contribution…
Abstract Number: 153 • 2015 ACR/ARHP Annual Meeting
Utility of Ultrasound Synovitis Assessment As a Predictor of Flares in Clinically Inactive Joints
Tomas Cazenave¹, Christian A. Waimann², Natalia Zamora¹, Gustavo Citera¹ and Marcos G. Rosemffet¹, ¹Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Hospital Dr. Hector Cura, Olavarria, Argentina
Background/Purpose: Several ultrasound (US) studies have shown a high frequency of inflammation in clinically inactive joints of rheumatoid arthritis (RA)patients. There is controversy in the…
Abstract Number: 434 • 2015 ACR/ARHP Annual Meeting
Duration of Remission By Currently Available Criteria Can Predict Physical Functioning, but Not Radiological Progression in Early Rheumatoid Arthritis Patients
Nicole P.C. Konijn¹, Lilian H.D. van Tuyl¹, Maarten Boers^1,2, D den Uyl¹, M.M. ter Wee¹, P.J.S.M. Kerstens^3,4, Alexandre E. Voskuyl⁵, Michael T. Nurmohamed^1,3, Dirkjan van Schaardenburg^3,6 and Willem F. Lems^1,3, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ²Epidemiology & Biostatistics, VU University medical center, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ⁴Rheumatology, Westfriesgasthuis, Hoorn, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, ⁶Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center, Amsterdam, Netherlands
Background/Purpose: Several sets of remission criteria have been developed. The ACR/EULAR criteria were validated against their potential to predict prognosis of rheumatoid arthritis (RA) [1].…
Abstract Number: 465 • 2015 ACR/ARHP Annual Meeting
MRI Bone Erosion at Baseline Predicts the Subsequent Radiographic Progression in Early-Stage RA Patients Who Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort
Mami Tamai¹, Yoshikazu Nakashima¹, Kazuhiko Arima², Junko Kita¹, Masataka Umeda¹, Shoichi Fukui¹, Ayako Nishino¹, Takahisa Suzuki¹, Yoshiro Horai¹, Akitomo Okada³, Tomohiro Koga¹, Shin-ya Kawashiri^1,2, Naoki Iwamoto¹, Kunihiro Ichinose¹, Satoshi Yamasaki⁴, Hideki Nakamura¹, Tomoki Origuchi⁵, Kiyoshi Aoyagi², Masataka Uetani⁶, Katsumi Eguchi⁷ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ²Department of Public Health, Nagasaki University, Nagasaki, Japan, ³Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁴Hiroshima University, Hiroshima, Japan, ⁵Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁶Department of Radiology and Radiation Research, Nagasaki University, Nagasaki, Japan, ⁷Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan
Background/Purpose: Given the improved detection of joint injury by MRI than by clinical examination, EULAR recommendations for the use of imaging of the joints in…
Abstract Number: 603 • 2015 ACR/ARHP Annual Meeting
Which Seronegative RA Patients Respond to Rituximab? – Preliminary Analysis of a Merged Clinical Trials Dataset
Elizabeth M.A. Hensor^1,2, Edward M. Vital^1,2 and Paul Emery^1,2, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Seronegative RA patients have inferior clinical response to rituximab [1]. However, there is significant heterogeneity in this group of patients for baseline clinical features…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].